How Do Dogs Get Meningitis: Causes, Signs, and Treatment

Dogs can develop meningitis from infections, immune disorders, and fungi. Learn the signs to watch for and how vets diagnose and treat this serious condition.

Most dogs with meningitis did not “catch” anything. The single most common form of the disease in dogs is immune-mediated, meaning the dog’s own immune system attacks the membranes surrounding the brain and spinal cord without any infection being present. Bacterial, fungal, and parasitic infections can also cause canine meningitis, but they account for a smaller share of cases than the immune-driven forms. Understanding which type your dog has matters enormously, because treatment for immune-mediated meningitis (suppressing the immune system) is essentially the opposite of treatment for an infection (supporting the immune system while killing the pathogen).

Immune-Mediated Meningitis Is the Most Common Type

When veterinary neurologists see a dog with meningitis, the leading diagnosis is usually one of two immune-mediated conditions: steroid-responsive meningitis-arteritis (SRMA) or meningoencephalomyelitis of unknown origin (MUO). Neither is caused by a virus, bacterium, or parasite. Instead, something goes wrong with immune regulation, and the body’s defenses turn on the central nervous system’s own tissues.

SRMA primarily inflames the meninges and the blood vessels that supply them, especially around the neck. Research shows that affected dogs have a shift in their immune response that drives excessive production of a particular antibody called IgA. Dogs with untreated SRMA have significantly elevated IgA levels in both their blood and cerebrospinal fluid, and measuring those levels is one of the main ways veterinarians confirm the diagnosis, with a sensitivity of about 91% and specificity of about 78%. The underlying immune imbalance appears to involve a skew toward a particular type of helper T-cell activity that promotes antibody overproduction, especially the signaling molecule IL-4. Nobody knows what triggers this cascade in the first place. Suspected triggers include environmental factors and a genetic predisposition, but no single cause has been pinpointed.

MUO is an umbrella term covering several related inflammatory brain diseases, including granulomatous meningoencephalomyelitis (GME), necrotizing meningoencephalitis (NME), and necrotizing leukoencephalitis (NLE). These conditions differ in where and how they damage the brain. GME forms clusters of immune cells around blood vessels, particularly in the white matter of the brain, cerebellum, and brainstem. NME, on the other hand, produces areas of tissue death and is strongly associated with autoantibodies that target the dog’s own brain cells. The cause of GME remains unknown, though an immune-mediated origin is widely suspected.

Bacterial Meningitis and How Infections Reach the Brain

Bacterial meningitis in dogs is less common than the immune-mediated forms, but it tends to be more acute and can escalate quickly. The bacteria involved are often ones that live harmlessly on the dog’s skin, in the gut, or in the upper respiratory tract until they gain access to the central nervous system. Two retrospective studies paint a fairly consistent picture of the culprits: Staphylococcus species, Streptococcus species, and Escherichia coli are among the most frequently identified.

Bacteria do not just wander into the brain on their own. They need a route through the blood-brain barrier, the tightly sealed lining of blood vessels that normally keeps pathogens out of the central nervous system. Research on E. coli isolated from a dog with septicemia and meningoencephalitis showed that the bacterium disrupts the architecture of this barrier by breaking down the proteins that hold the cells together, essentially prying open the gates. Once the barrier is compromised, the infection can worsen quickly, because inflammatory signals increase permeability even further, allowing more harmful substances and immune cells to flood into brain tissue.

One of the most common entry points for bacteria is the ear. Middle ear infections (otitis media) develop in a large proportion of dogs with chronic ear disease, and the close proximity of the middle and inner ear to the brainstem means infection can spread inward. In a study of 30 dogs with suspected ear-related brain infections, all dogs with brainstem lesions on MRI had a history of chronic or recurrent otitis. Other routes include dental infections, bite wounds near the skull, sinus infections, and bloodstream infections (septicemia) that seed the brain from a distant site.

Fungal, Parasitic, and Viral Causes

Fungal meningitis is uncommon in dogs overall, but it tends to be severe when it occurs. Fungal organisms like Cryptococcus, Aspergillus, and Coccidioides can invade the central nervous system and produce inflammation that looks like multifocal meningoencephalitis, brain granulomas, or inflammation of the ventricles inside the brain. Dogs often pick up these fungi from the environment, inhaling spores that then spread to the brain through the bloodstream. Geographic location matters: Coccidioides is concentrated in the southwestern United States and parts of Central and South America, while Cryptococcus has a broader distribution.

Parasitic causes are rare but worth knowing about. Two protozoan parasites, Neospora caninum and Toxoplasma gondii, have a particular affinity for nervous tissue in dogs. N. caninum shows a strong tropism for the central and peripheral nervous systems, while T. gondii targets the central nervous system and muscle tissue. Both can cause meningoencephalitis, sometimes alongside other infections. One case report from Argentina documented a dog with canine distemper virus, T. gondii, and N. caninum all present simultaneously, causing severe necrotizing meningoencephalitis. That said, active parasitic brain infection appears to be uncommon in dogs overall. A UK survey of 400 dogs with suspected meningoencephalitis found that active Toxoplasma infection was suspected in only about one in 400 dogs, and active Neospora infection in roughly 2%.

Canine distemper virus remains an important cause of viral meningoencephalitis, especially in unvaccinated or under-vaccinated dogs. The virus attacks the white matter of the brain and can cause demyelination, the stripping of the insulating sheath around nerve fibers. Vaccination has dramatically reduced distemper-related brain disease in well-vaccinated populations, but it persists in areas with low vaccination coverage and in shelter settings.

Recognizing the Signs

The hallmark signs of meningitis in dogs are neck pain and stiffness, often accompanied by fever. Dogs with SRMA classically present with cervical rigidity, meaning they hold their head low and resist any attempt to move it, along with a high temperature and obvious pain. These dogs may cry out when touched on the neck, walk with a hunched posture, or refuse to eat.

When inflammation extends beyond the meninges into the brain itself (meningoencephalitis), the signs become more varied and potentially more alarming. A study of 24 dogs with bacterial meningoencephalitis found that the majority had neurological deficits including altered mental state, loss of coordination, inability to walk, head tilt, and cranial nerve problems affecting the face and eyes. Seizures can occur as well, particularly with NME or GME, where the brain tissue itself is directly involved.

The speed of onset can offer a clue about the cause. SRMA tends to come on over a day or two with dramatic pain and fever. Bacterial meningitis can appear within hours, especially when associated with septicemia. MUO conditions like GME sometimes develop over days to weeks, with signs worsening gradually as new lesions form in the brain.

How Veterinarians Reach a Diagnosis

Diagnosing meningitis in dogs requires more than a physical exam. The single most informative test is analysis of cerebrospinal fluid (CSF), the liquid that bathes the brain and spinal cord. A veterinarian collects a small sample under general anesthesia, typically from the back of the skull or the lower spine, and examines it for abnormal cell counts, protein levels, and the presence of bacteria or other organisms. In inflammatory brain disease, CSF abnormalities were actually detected more often than abnormalities on MRI, making the spinal tap irreplaceable even in the age of advanced imaging.

MRI is the preferred imaging tool for evaluating the brain and spinal cord and is more sensitive than CT at picking up abnormalities in dogs with meningoencephalitis. However, MRI is not perfectly sensitive either. A comparison of imaging and CSF testing in 168 dogs found that some dogs with clearly inflammatory spinal fluid had normal-looking MRI scans, reinforcing the point that CSF analysis should be performed even when imaging looks clean.

The catch is that most CSF abnormalities are nonspecific. Elevated white blood cell counts tell you something is inflamed, but not why. Distinguishing SRMA from bacterial meningitis, or GME from a fungal granuloma, requires additional tests: bacterial and fungal cultures, antibody titers for specific organisms, IgA measurements for SRMA, and sometimes PCR testing to detect pathogen DNA. Even with all of these tools, a definitive diagnosis of GME or NME can technically only be confirmed by examining brain tissue, which is rarely done in living patients. In practice, MUO is diagnosed by ruling out infections and other causes.

Treatment for Immune-Mediated Forms

Because the immune system itself is the problem in SRMA and MUO, the backbone of treatment is immunosuppression. For SRMA, this means corticosteroids, usually prednisolone, started at doses high enough to shut down the inflammatory response and then gradually tapered over weeks to months. All dogs in published treatment trials responded to this approach initially. A recent randomized trial compared a short six-week taper to a longer six-month taper and found no significant difference in relapse rates between the two, which is reassuring for owners concerned about long-term steroid side effects.

For MUO conditions like GME and NME, treatment typically combines corticosteroids with a second immunosuppressive drug. The published evidence supports either cyclosporine or cytosine arabinoside as the most common additions. The steroid is usually tapered after the acute phase, with the second drug carrying the load for long-term control. Other drugs including leflunomide, mycophenolate mofetil, and combinations of these have been studied, with median survival times ranging from over a year to nearly three years depending on the agent used. One study found that adding cytosine arabinoside at the time of diagnosis on top of cyclosporine and prednisone did not improve outcomes compared to cyclosporine and prednisone alone, suggesting that more immunosuppression is not always better.

Treating Infectious Meningitis

When an infection is responsible, the treatment approach flips. Antibiotics are the cornerstone for bacterial meningitis, but choosing the right one is complicated by the blood-brain barrier. Under normal conditions, many common antibiotics barely penetrate into the spinal fluid. The good news is that meningitis itself changes the equation. Inflammation makes the barrier leakier, which actually allows certain antibiotics to reach the brain at much higher concentrations than they normally would. Research in dogs showed that the penetration of amoxicillin into cerebrospinal fluid increased roughly 31-fold when the meninges were inflamed, and ampicillin concentrations rose between 15- and 31-fold. This paradox, where the disease itself enables its own treatment, is one reason early aggressive antibiotic therapy can be effective.

Treatment courses for bacterial meningitis are long. In one case series of 24 dogs, the median duration of antibiotic treatment was eight weeks, with some dogs receiving antibiotics for up to 16 weeks. When the source of infection is an ear, surgical intervention such as removal of the ear canal and opening of the bulla (the bony chamber of the middle ear) may be necessary to eliminate the reservoir of bacteria. Corticosteroids were also given to the majority of dogs in that study, likely to control the inflammation that was damaging the brain alongside the infection.

Fungal meningitis requires antifungal drugs, often for months or longer. These cases carry a more guarded prognosis because antifungal agents penetrate the central nervous system poorly and fungal organisms are inherently harder to eliminate than bacteria.

Breed and Genetic Susceptibility

Certain breeds are dramatically overrepresented in specific forms of canine meningitis, which strongly suggests a genetic component. For SRMA, breeds that show up most often include Golden Retrievers, Bernese Mountain Dogs, Wirehaired Pointing Griffons, Boxers, and Beagles. Most affected dogs are young adults, typically under two years old.

For NME, the genetic links are even more specific. Pug dogs are famously susceptible, and research has shown that risk is closely tied to specific variants in a set of immune-system genes called the dog leukocyte antigen (DLA) class II complex. Sequencing just one gene in this complex, DQB1, can predict NME risk in Pugs as accurately as sequencing all three genes typically examined. Maltese dogs are also prone to NME, and a genome-wide study in that breed identified risk regions on two chromosomes, plus significant associations within the DLA II locus itself. The researchers found evidence of a shared genetic background across toy breeds that makes them susceptible to NME, though the strength of the effect varies by breed.

GME, by contrast, does not cluster in a few breeds as tightly. Small and toy breeds seem overrepresented as a group, but the genetic architecture is less clear than for NME. This distinction matters practically: if you own a Pug, Maltese, or Yorkshire Terrier and your dog develops progressive neurological signs, NME should be high on the list of concerns. If you own a young Bernese Mountain Dog with sudden neck pain and fever, SRMA is the more likely suspect.

Relapse and Long-Term Outlook

Relapse is one of the most frustrating aspects of canine meningitis for owners who thought their dog was cured. For SRMA, a prospective trial found that about a third of dogs relapsed at least once within a year of treatment, regardless of whether they were on a short or long steroid taper. Most dogs that relapsed did so only once, but a small proportion relapsed two or three times. The encouraging part is that relapses generally respond to restarting treatment.

For MUO, the factors that predict a worse outcome are more sobering. Dogs whose neurological signs did not fully resolve within six months of diagnosis, dogs that had a higher burden of neurological disability at presentation, and dogs whose signs had been present for more than a week before treatment began all had significantly higher relapse rates. This points to a practical takeaway: early diagnosis and prompt treatment improve the odds. Dogs that arrive at the neurologist already severely affected, or weeks into their illness, face an uphill battle.

Bacterial meningitis carries its own prognostic picture. In the 24-dog case series mentioned earlier, 20 of 24 dogs survived to leave the hospital, which is a better short-term survival rate than many owners expect. However, residual neurological deficits like a persistent head tilt or mild coordination problems were common, reported in about a third of survivors.

Emerging Biomarkers and Future Directions

One of the biggest hurdles in canine meningitis is that diagnosing the specific type often requires invasive testing and a process of elimination. Researchers are working on more targeted biomarkers that could speed up diagnosis. One promising approach uses high-density peptide microarrays, essentially panels of thousands of tiny protein fragments, to look for antibody patterns unique to specific diseases. In a study testing this method, dogs with SRMA showed a distinctive pattern of IgA antibodies binding to a specific fragment of an anti-inflammatory protein called IL-1 receptor antagonist. This binding pattern was absent in control dogs with a non-inflammatory spinal condition. This is still early-stage research, a screening method looking for candidate proteins rather than a ready-to-use clinical test. But it represents a direction that could eventually allow veterinarians to distinguish between forms of meningitis with a blood test rather than relying so heavily on CSF taps and imaging combined with clinical suspicion.

Genetic testing is another frontier. With the DLA associations in NME now well established, it is already technically possible to screen at-risk breeds for genetic susceptibility. Whether that translates into routine breeding decisions or early monitoring protocols remains to be seen, but the tools exist. For SRMA, where the genetic picture is fuzzier, researchers are still working to identify the specific genes involved. The hope is that better understanding of why certain dogs’ immune systems go haywire will eventually point toward more targeted therapies than the blunt instrument of broad immunosuppression.